Q-omics provides the consensus-scored FOXE1 profile across patient tissues and cancer cell-line models. FOXE1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FOXE1 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, FOXE1 RNA expression shows 16,309 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where FOXE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXE1 survival associations across molecular data types. FOXE1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXE1 RNA expression–survival associations across cancer types. High FOXE1 expression shows unfavorable associations in KIRC, UCEC, COAD and ACC, but favorable associations in HNSC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FOXE1 RNA expression.
This table summarizes FOXE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FOXE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXE1 shows lower tumor expression in THCA, KICH and BRCA and higher tumor expression in LUSC, LUAD and HNSC. The THCA box plot shows higher FOXE1 RNA expression in normal versus tumor tissue (log2 FC = −1.740, t-test p < 0.001).
This table shows molecular features associated with FOXE1 in patient tissues and cancer cell lines. In patient samples, FOXE1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SKIN.
